<DOC>
	<DOC>NCT02265510</DOC>
	<brief_summary>This is a study of INCB052793 given to patients with advanced malignancies that will be conducted in two phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy). Each study phase will have two parts; a dose escalation (Part 1) and an expansion (Part 2).</brief_summary>
	<brief_title>An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>Phase 1a Aged 18 years or older Histologically or cytologically confirmed solid tumor or hematologic malignancy Life expectancy of 12 weeks or longer Must have received ≥ 1 prior treatment regimen Must not be a candidate for potentially curative or standard of care approved therapy Phase 1b Aged 18 years or older Cohort A: Histologically or cytologically confirmed pancreatic adenocarcinoma, triplenegative breast cancer, urothelial cancer with at least 1 measurable or evaluable target lesion Cohorts B, C, D, E and G: Histologically confirmed multiple myeloma and measureable/evaluable disease Cohort F: Confirmed acute myeloid leukemia or myelodysplastic syndrome Cohort H: Individuals diagnosed with lymphoma Prior therapy: Cohort A: No more than 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy) Cohorts B, C, D, E and G: Must have relapsed from or have been refractory to ≥ 2 prior treatment regimens Cohort F: May have received any number of prior treatment regimens or be treatmentnaïve Cohort H: Must have relapsed from or have been refractory to available treatments Prior receipt of a JAK1 inhibitor (Phase 1a only) Known active central nervous system metastases and/or carcinomatous meningitis Eastern Cooperative Oncology Group (ECOG) performance status &gt; 2 Any known contraindications to the use of gemcitabine, nabpaclitaxel, dexamethasone, carfilzomib, bortezomib, lenalidomide, azacitidine, pomalidomide or PI3Kδ inhibitor (Phase 1b only, as appropriate to treatment cohort) Known human immunodeficiency virus infection, or evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>